Axel M Hillmer
Overview
Explore the profile of Axel M Hillmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
4978
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kreten F, Buttner R, Peifer M, Harder C, Hillmer A, Abedpour N, et al.
Cell Syst
. 2024 Nov;
15(11):1061-1074.e7.
PMID: 39541986
Prostate cancer (PCA) exhibits high levels of intratumoral heterogeneity. In this study, we developed a mathematical model to study the growth and genetic evolution of PCA. We explored the possible...
2.
Arolt C, Scheel A, Dugan M, Wild R, Richartz V, Holz B, et al.
NPJ Precis Oncol
. 2024 Nov;
8(1):259.
PMID: 39528799
Our recently published K1N2-score robustly predicts KEAP1/NFE2L2-mutations and pathway activation status, while its accessibility might be limited. We tested if the RNA expression data of six pathway-related genes and NQO1-IHC...
3.
Plum P, Hess T, Bertrand D, Morgenstern I, Velazquez Camacho O, Jonas C, et al.
Clin Transl Med
. 2024 Jun;
14(6):e1723.
PMID: 38877653
Background: Cholangiocarcinoma (CCA) is a fatal cancer of the bile duct with a poor prognosis owing to limited therapeutic options. The incidence of intrahepatic CCA (iCCA) is increasing worldwide, and...
4.
Garcia-Marquez M, Thelen M, Bauer E, Maas L, Wennhold K, Lehmann J, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38631707
Background: The individual HLA-I genotype is associated with cancer, autoimmune diseases and infections. This study elucidates the role of germline homozygosity or allelic imbalance of HLA-I loci in esophago-gastric adenocarcinoma...
5.
Liu X, Zhang K, Kaya N, Jia Z, Wu D, Chen T, et al.
Nat Commun
. 2024 Apr;
15(1):3169.
PMID: 38609353
Solid tumors are complex ecosystems with heterogeneous 3D structures, but the spatial intra-tumor heterogeneity (sITH) at the macroscopic (i.e., whole tumor) level is under-explored. Using a phylogeographic approach, we sequence...
6.
Alidousty C, Becker A, Binot E, Hillmer A, Merkelbach-Bruse S, Budde B, et al.
Gene
. 2023 Nov;
895:148018.
PMID: 37981082
Introduction: In contrast to lung adenocarcinoma (LUAD), targetable genetic alterations are less frequently detected in squamous cell carcinoma of the lung (LUSC). Over the last years, gene fusions have become...
7.
Arolt C, Scheffler M, Hillmer A
J Thorac Oncol
. 2023 Oct;
18(11):e128-e129.
PMID: 37879769
No abstract available.
8.
Lorenz C, Hillmer A, Bragelmann J
Signal Transduct Target Ther
. 2023 Aug;
8(1):291.
PMID: 37553337
No abstract available.
9.
Hess T, Maj C, Gehlen J, Borisov O, Haas S, Gockel I, et al.
EBioMedicine
. 2023 Jul;
94:104709.
PMID: 37480624
No abstract available.
10.
Arolt C, Dugan M, Wild R, Richartz V, Holz B, Scheel A, et al.
J Thorac Oncol
. 2023 Jul;
18(11):1550-1567.
PMID: 37473958
Introduction: Activation of the antioxidant KEAP1/NFE2L2 (NRF2) pathway leads to increased glutamine dependence and an aggressive phenotype in NSCLC. Because this pathway has been explored as a clinical target, we...